Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility under the company's ShareReward Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details the acquisition of Ordinary Shares by specific executives on October 9, 2013, at a price of 1560.921 pence per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: October 9, 2013.
- Share Price: 1560.921 pence per Ordinary Share.
- Participants: Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr R G Connor, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Transaction Type: Acquisitions under the ShareReward Plan, consisting of personal contributions matched by company contributions.
- Volume: Most participants acquired 8 shares via personal contribution and 8 via company matching; Mr P C Thomson acquired 7 shares in each category.